ANDOVER, Mass., Feb. 26, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter and year ended December 31, 2023.
Recent Highlights
"2023 was a great year for TransMedics as we achieved 159% revenue growth and launched TransMedics transplant logistics services to provide a more operationally and economically efficient service to our transplant program users," said Waleed Hassanein, MD, President and Chief Executive Officer. "We are humbled and excited that the use of OCS technology and our NOP program were primary drivers in increasing the national heart and liver transplant volumes by 12% in 2023. This double-digit growth in transplant volumes has not been witnessed in several years."
Fourth Quarter 2023 Financial Results
Total revenue for the fourth quarter of 2023 was $81.2 million, a 159% increase compared to $31.4 million in the fourth quarter of 2022. The increase was due primarily to the increase in utilization of the OCS through the National OCS Program ("NOP") as well as additional revenue generated by the addition of TransMedics logistics services.
Gross margin for the fourth quarter of 2023 was 59% compared to 66% in the fourth quarter of 2022.
Operating expenses for the fourth quarter of 2023 were $45.3 million compared to $27.5 million in the fourth quarter of 2022. The increase in operating expense was driven primarily by increased investment throughout the organization to support the growth of the company. Fourth quarter operating expenses in 2023 included $5.5 million of stock compensation expense compared to $3.0 million of stock compensation in the fourth quarter of 2022.
Net income for the fourth quarter of 2023 was $4.0 million compared to net loss of $6.7 million in the fourth quarter of 2022.
Full Year 2023 Financial Results
Total revenue for the full year of 2023 was $241.6 million, a 159% increase compared to $93.5 million in the full year of 2022. The increase was due primarily to the increase in utilization of the OCS through the NOP as well as additional revenue generated by the addition of TransMedics logistics services.
Gross margin for the full year of 2023 was 64% compared to 70% in the full year of 2022.
Operating expenses for the full year of 2023 were $182.8 million compared to $96.7 million in the full year of 2022. The increase in operating expense was driven by investment throughout the organization to support the growth in the business as well as an acquired in-process research and development charge of $27.2 million and an additional $2.0 million in non-recurring acquisition-related costs, both in the third quarter of 2023. Full year 2023 operating expenses included $19.4 million of stock compensation expense compared to $10.3 million in 2022.
Net loss for the full year of 2023 was $25.0 million compared to $36.2 million in the full year of 2022.
Cash was $394.8 million as of December 31, 2023.
2024 Financial Outlook
TransMedics expects total revenue for full-year 2024 to be in the range of $360 million to $370 million, which represents 49% to 53% growth compared to the company's prior year revenue.
Webcast and Conference Call Details
The TransMedics management team will host a conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT on Monday, February 26, 2024. Investors interested in listening to the conference call may do so by dialing (866) 807-9684 for domestic callers or (412) 317-5415 for international callers and ask to be joined into the TransMedics call. A live and archived webcast of the event will be available on the "Investors" section of the TransMedics website at www.transmedics.com.
About TransMedics Group, Inc.
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.
Forward-Looking Statements
This press release contains forward-looking statements with respect to, among other things, our full-year guidance, and statements about our operations, financial position, and business plans. These forward-looking statements are subject to a number of risks and uncertainties. Our management cannot predict all risks, nor can we assess the impact of all factors or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in or implied by any forward-looking statements we may make. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated in or implied by the forward-looking statements. Some of the key factors that could cause actual results to differ include: that we continue to incur losses; our ability to attract and retain key personnel; our existing and any future indebtedness, including our ability to comply with affirmative and negative covenants under our credit agreement to which we will remain subject until maturity; the fluctuation of our financial results from quarter to quarter; our need to raise additional funding and our ability to obtain it on favorable terms, or at all; our ability to use net operating losses and research and development credit carryforwards; our dependence on the success of the OCS; our ability to expand access to OCS through the NOP; our ability to scale our manufacturing and sterilization capabilities to meet increasing demand for our products; the rate and degree of market acceptance of the OCS; our ability to educate patients, surgeons, transplant centers and private payors of benefits offered by the OCS; our ability to improve the OCS platform and develop the next generation of the OCS products; our dependence on a limited number of customers for a significant portion of our net revenue; our ability to maintain regulatory approvals or clearances for our OCS products in the United States, the European Union, and worldwide; our ability to adequately respond to FDA, or other competent authorities, follow-up inquiries in a timely manner; performance of our third-party suppliers and manufacturers; our use of third parties to transport donor organs and medical personnel for our NOP and our ability to maintain and grow our aviation capabilities to support our NOP to reduce dependence on third party transportation, including by means of the acquisition of fixed-wing aircraft or other acquisitions, joint ventures or strategic investments; our ability to maintain Federal Aviation Administration or other regulatory licenses or approvals for our aircraft services; price increases of the components of our products and maintenance, parts and fuel for our aircraft; the timing or results of post-approval studies and any clinical trials for the OCS; our manufacturing, sales, marketing and clinical support capabilities and strategy; attacks against our information technology infrastructure; the economic, political and other risks associated with our foreign operations; our ability to protect, defend, maintain and enforce our intellectual property rights relating to the OCS and avoid allegations that our products infringe, misappropriate or otherwise violate the intellectual property rights of third parties; the pricing of the OCS, as well as the reimbursement coverage for the OCS in the United States and internationally; regulatory developments in the United States, European Union and other jurisdictions; the extent and success of competing products that are or may become available; our ability to service our 1.50% convertible senior notes, due 2028; the impact of any product recalls or improper use of our products; risks related to retaining key Summit employees and risks related to providing logistics and aviation services and owning aircraft; our estimates regarding revenues, expenses and needs for additional financing; and other factors that may be described in our filings with the Securities and Exchange Commission (the "SEC"). Additional information will be made available in our annual and quarterly reports and other filings that we make with the SEC. The forward-looking statements in this press release speak only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and we are not able to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law.
Investor Contact:
Brian Johnston
332-895-3222
This email address is being protected from spambots. You need JavaScript enabled to view it.
TransMedics Group, Inc. | ||||||||
Three Months Ended December 31, | Year ended December 31, | |||||||
2023 | 2022 | 2023 | 2022 | |||||
Revenue: | ||||||||
Net product revenue | $ 51,874 | $ 25,074 | $ 176,069 | $ 79,234 | ||||
Service revenue | 29,300 | 6,301 | 65,554 | 14,225 | ||||
Total revenue | 81,174 | 31,375 | 241,623 | 93,459 | ||||
Cost of revenue: | ||||||||
Cost of net product revenue | 14,065 | 5,281 | 41,015 | 16,970 | ||||
Cost of service revenue | 19,185 | 5,391 | 46,515 | 11,217 | ||||
Total cost of revenue | 33,250 | 10,672 | 87,530 | 28,187 | ||||
Gross profit | 47,924 | 20,703 | 154,093 | 65,272 | ||||
Gross Margin | 59 % | 66 % | 64 % | 70 % | ||||
Operating expenses: | ||||||||
Research, development and clinical trials | 10,761 | 5,756 | 36,055 | 26,812 | ||||
Acquired in-process research and development expenses | — | — | 27,212 | — | ||||
Selling, general and administrative | 34,560 | 21,726 | 119,553 | 69,897 | ||||
Total operating expenses | 45,321 | 27,482 | 182,820 | 96,709 | ||||
Income (loss) from operations | 2,603 | (6,779) | (28,727) | (31,437) | ||||
Other income (expense): | ||||||||
Interest expense | (3,605) | (1,007) | (10,791) | (3,726) | ||||
Other income (expense), net | 4,865 | 1,085 | 12,847 | (1,002) | ||||
Total other income (expense), net | 1,260 | 78 | 2,056 | (4,728) | ||||
Income (loss) before income taxes | 3,863 | (6,701) | (26,671) | (36,165) | ||||
(Provision) benefit for income taxes | 168 | (19) | 1,643 | (66) | ||||
Net income (loss) | $ 4,031 | $ (6,720) | $ (25,028) | $ (36,231) | ||||
Net income (loss) per share: | ||||||||
Basic | $ 0.12 | $ (0.21) | $ (0.77) | $ (1.23) | ||||
Diluted | $ 0.12 | $ (0.21) | $ (0.77) | $ (1.23) | ||||
Weighted average common shares outstanding: | ||||||||
Basic | 32,644,525 | 32,010,621 | 32,517,372 | 29,556,633 | ||||
Diluted | 34,179,059 | 32,010,621 | 32,517,372 | 29,556,633 | ||||
TransMedics Group, Inc. | ||||
December 31, | ||||
2023 | 2022 | |||
Assets | ||||
Current assets: | ||||
Cash | $ 394,812 | $ 201,182 | ||
Accounts receivable | 63,576 | 27,611 | ||
Inventory | 44,235 | 20,605 | ||
Prepaid expenses and other current assets | 8,031 | 2,896 | ||
Total current assets | 510,654 | 252,294 | ||
Property, plant and equipment, net | 173,941 | 19,223 | ||
Operating lease right-of-use assets | 6,546 | 5,130 | ||
Restricted cash | 500 | 500 | ||
Goodwill | 11,990 | — | ||
Acquired intangible assets, net | 2,354 | — | ||
Other non-current assets | 62 | — | ||
Total assets | $ 706,047 | $ 277,147 | ||
Liabilities and Stockholders' Equity | ||||
Current liabilities: | ||||
Accounts payable | $ 12,717 | $ 3,341 | ||
Accrued expenses and other current liabilities | 38,221 | 18,635 | ||
Deferred revenue | 1,961 | 241 | ||
Operating lease liabilities | 2,035 | 1,444 | ||
Total current liabilities | 54,934 | 23,661 | ||
Convertible senior notes, net | 447,140 | — | ||
Long-term debt, net | 59,064 | 58,696 | ||
Operating lease liabilities, net of current portion | 7,707 | 7,415 | ||
Total liabilities | 568,845 | 89,772 | ||
Total stockholders' equity | 137,202 | 187,375 | ||
Total liabilities and stockholders' equity | $ 706,047 | $ 277,147 | ||
| Last Trade: | US$77.35 |
| Daily Change: | -5.57 -6.72 |
| Daily Volume: | 2,881,168 |
| Market Cap: | US$2.580B |
October 28, 2024 April 30, 2024 February 28, 2024 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
